Ketohexokinase: A Potential Drug Target Or Biomarker (G3795)

Target Name: KHK

NCBI ID: G3795

Content of Review Report on KHK Target / Biomarker

KHK

Ketohexokinase: A Potential Drug Target Or Biomarker

Ketohexokinase (KHK) is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and kidneys. It is a key enzyme in the ketogenic acid-base (KAB) transporter system, which is responsible for regulating the flow of ketones into the cells.

KHK has been identified as a potential drug target or biomarker for several reasons. First, KHK has been shown to play a role in a variety of diseases, including epilepsy, migraine, and diabetes. Second, KHK has been shown to be involved in the regulation of cellular processes that are important for brain function, such as the production of neurotransmitters and the regulation of inflammation.

In addition to its potential therapeutic applications, KHK has also been shown to be a valuable research tool for studying the underlying mechanisms of several diseases. For example, studies have shown that modulating KHK activity can be a useful way to treat epilepsy by reducing the production of hyperactive neurons. Similarly, by regulating the activity of KHK, researchers have been able to develop new treatments for migraine and other neurological conditions.

Overall, KHK is a protein that has the potential to be a valuable drug target or biomarker for a variety of diseases. Further research is needed to fully understand its role and to develop effective treatments.

Protein Name: Ketohexokinase

Functions: Catalyzes the phosphorylation of the ketose sugar fructose to fructose-1-phosphate

The "KHK Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KHK comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets